medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Number 1

<< Back Next >>

Ann Hepatol 2002; 1 (1)

Obesity-related non-alcoholic steatohepatitis and TGF-β1serum levels in relation to morbid obesity

Sepúlveda-Flores RN, Vera-Cabrera L, Flores-Gutiérrez JP, Maldonado-Garza H, Salinas-Garza R, Zorrilla-Blanco P, Bosques-Padilla FJ

Language: English
References: 26
Page: 36-39
PDF size: 197.28 Kb.


Text Extraction

Non-alcoholic steatohepatitis (NASH) can vary from mild hepatic inflammation and steatosis to cirrhosis, and is most frequently associated with obesity, Type 2 diabetes mellitus, hypertension, and the female gender. The prevalence of fatty liver and NASH in the general population is 20% and 3%, respectively. In Western countries, 15–20% of the population is obese and 74–90% of them exhibit fatty changes in liver biopsies. We assessed the prevalence of NASH in morbidly obese patients and evaluated serum TGF-β1 concentrations in different stages of liver fibrosis. Thirty-five obese patients were evaluated, nine male and 26 female. Their mean body mass index (BMI) was 43.62 ± 7.92 kg/m2. Liver biopsies were evaluated by light microscopy; graded and staged according to Brunt’s system. Serum obtained from patients was used to detect TGF-b1 concentrations by an ELISA method. Serum alanine transaminase (ALT) levels were elevated in four of the patients and the mean level was 49.98 ± 94.7 (8–65 IU/L). NASH was diagnosed in 32 (91%) of the biopsies, and the most common pattern seen was mixed, predominantly macrovesicular steatosis. Some degree of fibrosis was seen in 34 (97%) of the biopsies and 22 (63%) were at stage 2 (range 1–3). Serum concentrations of TGF-β1 had no relationship with the stages of fibrosis. In conclusion, NASH and fibrosis are common in our obese patients, as observed in other studies. TGF-b1 may play a key role in liver fibrogenesis.


REFERENCES

  1. Organización Mundial de la Salud: http://www.who.int/whosis.

  2. De la Mora G, Olivera M, de la Cerda R, Arista J, Kershenobich D, Uribe M. Esteatohepatitis no alcohólica: Experiencia de 10 años en el Instituto Nacional de la Nutrición Salvador Zubirán. Rev Inv Clin 1994; 46:85–92.

  3. Williams EJ, Gaá MDA, Brigstock DR, Arthur MJP, Benyon RC. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000; 32:754–61.

  4. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and Nutritional Considerations in Nonalcoholic Fatty Liver. Hepatology 2000; 32:310.

  5. Friedman SL, Maher JJ, Bissel DM. Mechanisms and Therapy of Hepatic Fibrosis: Report of the AASLD single Topic Basic Research Conference. Hepatology 2000; 32:1403–8.

  6. Matteoni CA, Younoussi ZM, Gramlich T, Boparai N, Hu YC, McCullough AJ. Nonalcoholic Fatty Liver Disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.

  7. Marceu P, Biron S, Hould FS, Marceu S, Simard S, Thung SN, Kral JG. Liver Pathology and the Metabolic Syndrome X in Severe Obesity. J Clin Endocrinol & Metab 1999; 84: 1513-7.

  8. García-Monzón C, Martín-Pérez E, Lacono OL, Fernández-Bermejo M, Majano PL, Apolinario A, Larráñaga E, et al. Characterization of Pathogenic and Prognostic Factors of Nonalcoholic Steatohepatitis Associated with Obesity. J Hepatol 2000; 33:716–24.

  9. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodoru I, Khalil L, et al. Liver Fibrosis in Overweight Patients. Gastroenterology 2000; 118:1117–23.

  10. Rockey DC. Pathophysiology of Disease: The Cell and Molecular Biology of Hepatic Fibrogenesis. Clin Liver Dis 2000; 4: 1-36.

  11. Vera-Cabrera L, Handzel V, Laszlo A. Development of an Enzyme Linked Immunosorbent Assay (ELISA) Combines With a Streptavidin Biotin and Enzyme Amplification Method to Detect Anti-2, 3-di-oacyltrehalose (DAT) Antibodies in Patients with Tuberculosis. J Immun Met 1994; 177:69–77.

  12. Border NA, Noble NA. Mechanisms of disease: Transforming Growth Facto (beta) in Tissue Fibrosis. N Eng J Med 1994; 331: 1286-1292.

  13. Tilg H, Diehl AM. Cytokines in Alcoholic and Nonalcoholic steatohepatitis. N Engl J Med 2000; 343:1467–76.

  14. Streetz KL, Luedde T, Manus MP, Trautwein C. Interleukins 6 and Liver Regeneration. Gut 2000; 47:303–12.

  15. Tsai JF, Chuang LY, Jang JE, Yang ML, Chang WY, Hsich MY, et al. Clinical Relevance of Transforming Growth Factor b1 as an indicator of Hepatic Function Impairment in Liver Cirrhosis. Medicine 1997; 76: 213-226.

  16. Blobe GC, Scieman NP, Lodis HF. Role of Transforming Growth Factor b in Human Disease. N Engl J Med 2000; 342:1350–8.

  17. George J, Roulot D, Kotelianski VE, Bissel DM. In Vivo inhibition of rat stellate cell activation by soluble transforming growth factor b type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96;12719–24.

  18. Roulot D, Seucsik AM, Coste T, Strosberg AD, Marullo S. Role of Transforming Growth Factor b type II receptor in Hepatic Fibrosis: Studies of Human Chronic Hepatitis C and Experimental Fibrosis in Rats. Hepatology 1999; 29:1730–8.

  19. Flisiak R, Pytel-Krolezuk B, Prokopowicz D. Circulating Transforming Growth Factor b1 as an indicator of Hepatic Function impairment in Liver Cirrhosis. Cytokine 2000; 12: 677–81.

  20. Flisiak R, Pytel-Krolezuk B, Prokopowicz D. Circulating Transforming Growth Factor b1 as an indicator of Hepatic Function impairment in Liver Cirrhosis. Cytokine 2000; 12: 677–81.

  21. Murawaki Y. Plasma transforming growth factor beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1998; 13:680–4.

  22. Brunt EM. Nonalcoholic Steatohepatitis: Definition and Pathology. Sem Liv Dis 2001; 21:3–16.

  23. Oh S, Afdhal NH. Hepatic Fibrosis: Are any of the serum markers useful? Current Gastroenterology Reports 2001; 3:12–18.

  24. Friedman SL. Seminars in Medicine of the Beth Israel Hospital Boston: The Cellular Basis of Hepatic Fibrosis-Mechanisms and Treatment Strategies. N Engl J Med 1993; 328: 1828-1835.

  25. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M et al. Nonalcoholic Steatohepatitis, Insulin Resistance, and Metabolic Syndrome: Further Evidence for an Etiologic Association. Hepatology 2002; 35:367–72.

  26. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G et al. Tumor necrosis factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122:274–80.




2020     |     www.medigraphic.com